Company Overview of Neuraltus Pharmaceuticals, Inc.
Neuraltus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for the treatment of neurodegenerative diseases. Its products include NP001 that regulates macrophage activation for targeting diseases, such as amyotrophic lateral sclerosis, Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis; and NP002, a small molecule and nicotinic receptor agonist to reduce dyskinesias, a primary side effect of L-dopa treatment of Parkinson’s disease. The company’s products also include NP003, an orally bioavailable small molecule to treat lysosomal storage diseases, such as Fabry’s disease and Gaucher’s disease. Neuraltus Pharmaceuticals, Inc. was incorp...
2483 East Bayshore Road
Palo Alto, CA 94303
Founded in 2004
Key Executives for Neuraltus Pharmaceuticals, Inc.
Chief Executive Officer and President
Co-Founder and Chief Operating Officer
Compensation as of Fiscal Year 2014.
Neuraltus Pharmaceuticals, Inc. Key Developments
Neuraltus Pharmaceuticals, Inc. Announces Promising Efficacy Results of the Phase 2 Clinical Program of Np001 for the Treatment of Amyotrophic Lateral Sclerosis
Sep 17 14
Neuraltus Pharmaceuticals, Inc. announced promising efficacy results of the company's Phase 2 clinical program of NP001 for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease) are being highlighted in an oral presentation at the inaugural Summit of the ALS Research Group, being held in Bloomington, Minnesota, September 17-19, 2014. According to a post hoc analysis, administration of a high dose of NP001 (2mg/kg) was associated with a halt in disease progression in 27% of patients, approximately 2.5 times greater than the percentage in patients on placebo (10%). The researchers determined that two major plasma factors -- Interleukin-18 (IL-18) and lipopolysaccharide (LPS), both markers of inflammation -- may differentiate NP001 responders from non-responders. In the analysis, the responder population was shown to have had significantly higher levels of IL-18, a cytokine involved in inflammation-driven cell death, than the non-responders at baseline (p=0.02). Additionally, all NP001 responders had detectable levels of LPS in their plasma, signifying abnormal macrophage function, whereas none of the placebo non-progressors had detectable LPS at baseline. NP001 is a small molecule regulator of inflammatory macrophage activity. Aberrant macrophage activity is believed to be a significant contributor to the pathology underlying ALS. Neuraltus' NP001 is designed to restore the normal functioning of macrophages within the central nervous system. Overall, study efficacy results demonstrated positive trends in the ability of NP001 to slow the rate of disease progression, ranging from 13 to 19% in multiple parameters of clinical benefit, although these pre-defined endpoints did not reach statistical significance. The benefit of NP001 related to the degree of baseline inflammation in patients. Those patients with greater baseline inflammation and who received the high dose of NP001 experienced a 44% greater slope improvement (positive trend did not reach significance, however). Further, NP001 was found to be generally safe and well-tolerated in the study.
Neuraltus Pharmaceuticals Announces Executive Changes
Oct 8 13
Neuraltus Pharmaceuticals, Inc. announced that Richard L. Casey has been named President and Chief Executive Officer, effective immediately. Mr. Casey brings extensive operational and senior management experience within the biopharma industry, including as the former Chairman and CEO of Scios. He replaces Neuraltus' Interim CEO John Walker. Prior to joining Scios, Mr. Casey was Executive Vice President, Pharmaceuticals, at ALZA Corporation, responsible for all manufacturing, marketing and business development activities at the company.
Neuraltus Pharmaceuticals, Inc. Presents at 12th Annual BIO Investor Forum, Oct-09-2013 12:00 PM
Oct 1 13
Neuraltus Pharmaceuticals, Inc. Presents at 12th Annual BIO Investor Forum, Oct-09-2013 12:00 PM. Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|